GeneStrat® (ddPCR & NGS)
Detection of actionable genomic alterations in advanced lung cancer
CommercialActive
Key Facts
Indication
Detection of actionable genomic alterations in advanced lung cancer
Phase
Commercial
Status
Active
Company
About Biodesix
Biodesix is a publicly-traded diagnostic company with a mission to transform patient care through timely, personalized diagnostics, primarily in lung cancer. The company has successfully commercialized a suite of blood-based tests, including the FDA-cleared Nodify Lung® and GeneStrat® tests, which are supported by its proprietary AI-driven multi-omics platform and real-world Biodesix Lung Database®. Its strategy is twofold: expanding the clinical adoption of its diagnostic tests while capitalizing on its platform and operational expertise through a growing diagnostic development services business for life sciences partners.
View full company profile